Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade.
Alessandro BrancatellaIsabella LupiLucia MontanelliDebora RicciNicola ViolaDaniele SgròLucia AntonangeliChiara SardellaSandra BrogioniPaolo PiaggiEleonora MolinaroFrancesca BianchiMichele AragonaAndrea AntonuzzoAndrea SbranaMaurizio LucchesiAntonio ChellaAlfredo FalconeStefano Del PratoRossella EliseiClaudio MarcocciPatrizio CaturegliFerruccio SantiniFrancesco LatrofaPublished in: Journal of the Endocrine Society (2021)
Administration of PD1- or PD-L1-blocking antibodies may induce 2 different forms of thyrotoxicosis that appear similar in clinical severity at onset: a type 1 characterized by persistent hyperthyroidism that requires treatment with MMI, and a type 2, characterized by destructive and transient thyrotoxicosis that evolves to hypothyroidism or euthyroidism. Thyroid scintigraphy and ultrasound help in differentiating and managing these 2 forms of iatrogenic thyrotoxicosis.